Greater Asia News
Astellas Establishes Open Innovation Hub for Tumor Microenvironment Research with Cutting-Edge Spatial Biology, in Mitsui Fudosan’s “MITSUI LINK-Lab KASHIWA-NO-HA 1”
Astellas Pharma Inc. (TSE: 4503) and Mitsui Fudosan Co., Ltd. (TSE: 8801) announced today that Astellas will establish a "TME imaging and interactive research for innovation (TME iLab)" open innovation hub in October, 2023 in "MITSUI LINK-Lab KASHIWA-NO-HA 1" (Kashiwa City, Chiba Prefecture, "the Lab") operated by Mitsui Fudosan.
Sosei Heptares Provides Update on Lotiglipron Development
osei Group Corporation (“the Company”; TSE: 4565) notes the decision by its partner Pfizer to prioritize the development of clinical-stage GLP-1 receptor agonist candidate danuglipron for the treatment of diabetes and obesity and as a result has discontinued the development of lotiglipron.
Phase 3b Trial of Fezolinetant Shows Positive Topline Results for Treatment of VMS Due to Menopause
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive topline results from the Phase 3b DAYLIGHT clinical trial for fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause.
SK bioscience and the Peter Doherty Institute for Infection and Immunity Join Forces Against Influenza
SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that the company has signed a research collaboration agreement on influenza research with the Doherty Institute.
Dyadic Announced an MoU with Bangladesh’s State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity
JUPITER, Fla. and DHAKA, Bangladesh, June 21, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that it has entered into a Memorandum of Understanding (“MoU”) with Essential Drugs Company Limited (EDCL), the state owned pharmaceutical company under the Ministry of Health and Family Welfare of Bangladesh to facilitate biopharmaceutical research, pre-clinical development, cGMP production, clinical trials, regulatory and other relevant areas of interest in Bangladesh.
HistoIndex Presents Advancements in AI-powered Stain-free Tissue Imaging for NASH Clinical Trials at EASL Congress 2023
SINGAPORE, June 21, 2023 /PRNewswire/ -- HistoIndex today announced that the Company, alongside its collaborators, will present new data on its novel stain-free tissue imaging technology using clinically validated artificial intelligence (AI) algorithms at the EASL Congress, taking place June 21-24, 2023.
Zeta Surgical Announces Successful Treatment of First Patient in Neurosurgical Navigation Clinical Trial at Singapore’s National Neuroscience Institute
SINGAPORE, June 22, 2023 /PRNewswire/ -- Zeta Surgical, a surgical robotics and mixed reality company, has successfully treated its first patient using the Zeta Cranial Navigation System as part of their first-in-human trial at Singapore's National Neuroscience Institute (NNI).
AWAK Technologies and Singapore General Hospital launch pre-pivotal clinical trial of wearable peritoneal dialysis device
SINGAPORE, June 19, 2023 /PRNewswire/ -- AWAK Technologies (AWAK) and Singapore General Hospital (SGH) announce the launch of a pre-pivotal clinical trial with the enrolment of their first subject to study the safety and efficacy of an improved Automated Wearable Artificial Kidney Peritoneal Dialysis (AWAK PD) device.
ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakima in Japan
ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan
Sun Pharma Announces Health Canada Approval of (PR)WINLEVI® (clascoterone cream 1%) for Topical Treatment of Acne
MUMBAI, India and BRAMPTON, ON, June 19, 2023 /CNW/ - Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited (Reuters: SUN.BO) (Bloomberg: SUNP IN) (NSE: SUNPHARMA) (BSE: 524715), "Sun Pharma" is pleased to announce Health Canada's approval of PrWINLEVI (clascoterone cream 1%).
